logo
Share SHARE
FONT-SIZE Plus   Neg

Aeterna Zentaris' Phase3 Perifosine Trial Fails To Meet Primary Endpoint

Late-stage oncology drug development company Aeterna Zentaris Inc. (AEZS, AEZ.TO) said its Phase 3 trial evaluating perifosine in refractory advanced colorectal cancer patients failed to meet primary endpoint. Trading for Aeterna halted in early morning hours and shares are currently down more than 55 percent on the Nasdaq.

The focus of the X-PECT study was improvement of overall survival with perifosine in comparison with capecitabine + placebo. The trial involved 468 patients in 65 sites in the U.S and the study was conducted by the Company's North American licensee partner, Keryx Biopharmaceuticals, Inc. (KERX).

Aeterna Zentaris said it is very disappointed that the trial result. The company will continue further data analyses in collaboration with our licensee partners, in order to determine the future development strategy for perifosine.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Come weekends and the ride sharing company Lyft in association with the beer brand Budweiser will offer free travel for short distances. The program is aimed at discouraging drunk driving on holidays. The offer of 150,000 free trips will be available in 10 states, all through the year. Chinese Internet giant Baidu, Inc. on Wednesday announced the release of Apollo 1.5, the second generation of its Apollo open-source autonomous vehicle software. The company also said it plans to set up a 10 billion yuan, or $1.5 billion Apollo self-driving car fund to invest in 100 autonomous driving projects in the next three years. Facebook Inc. said it is tightening controls on its advertising targeting policies and tools after a ProPublica expose last week found that advertisers on the social media site were able to target users interested in anti-Semitic topics. The company clarified that it has long had a firm policy against hate on Facebook.
comments powered by Disqus
Follow RTT